Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.

ABSTRACT:

Purpose

Ipilimumab is designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T cell responses. In studies of predominantly Caucasian patients with advanced melanoma, ipilimumab was associated with durable response, long-term survival benefit, and a manageable safety profile. This phase II study assessed the safety of ipilimumab in Japanese patients with unresectable stage III or IV melanoma.

Methods

Patients received ipilimumab 3 mg/kg every 3 weeks for four doses. The database lock for the original analysis was in August 2014. Overall survival, progression-free survival, and data on deaths were based on an updated, follow-up analysis (database lock April 2015).

Results

Data are reported from 20 patients. Fifteen patients (75 %) received all four dose

SUBMITTER: Yamazaki N 

PROVIDER: S-EPMC4612321 | biostudies-literature | 2015 Nov

REPOSITORIES: biostudies-literature